Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Should I Stop Taking Zetia?Posted: January 15, 2008After Merck & Co. and Schering-Plough Corp. admitted that Vytorin -- a combination of Zetia and Zocor (simvastatin) -- worked no better than an older, generic medication to reduce plaques in arteries, Dr. Steven Nissen, head of cardiology at the Cleveland Clinic in Ohio, immediately called for a "moratorium" on the use of Vytorin and Zetia, according to a story on Bloomberg.com (see coverage here). My question is this: Should I stop taking Zetia that was prescribed to me by my cardiologist, who--although I respect his judgment--is no head of cardiology at a renowned medical center? Why hasn't my doctor called me? What information can I find about this on the Zetia product site? Why aren't Merck and Schering-Plough doing PSAs to assure patients about their products? I don't know if I have the answers to all these questions, but at least I ASK them and suggest that their is something very wrong in all this, which you can read more about in today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Direct-to-Consumer Advertising Volume Two: DTC in the New Era 
DTC advertising is set for major changes in light of public criticism, but also in reaction to the changing reality of the marketplace where there is less need for a one size fits all solution. DTC must evolve and marketers must pay more attention to measuring and improving its effectiveness. Otherwise, billions of dollars will continue to be wasted. This volume is devoted to DTC best practices with a focus on techniques for improving DTC efficacy and return on investment, which is generally considered to be declining.
Order both Volume One and Volume Two and SAVE! (Click Here) Order and pay for Volume Two now using your credit card. ONLY $29.95
If you wish to be pay by check or credit card off-line, please use: |